Market Place
Sourcing Support
Catalyst Pharma Announces Settlement of U.S. Patent Litigation and Resolution
12 Jul 2022 //
GLOBENEWSWIRE
Catalyst Pharma Reports that Ruzurgi`s FDA Marketing Approval is No Longer Valid
03 Feb 2022 //
GLOBENEWSWIRE
Catalyst Pharma Receives Issuance of Mandate by the U.S. Court of Appeals
28 Jan 2022 //
GLOBENEWSWIRE
Enforcement Report - Week of October 6, 2021
06 Oct 2021 //
FDA
Catalyst one-ups Jacobus, FDA in Firdapse exclusivity appeal
02 Oct 2021 //
FIERCEPHARMA
Jacobus Pharmaceuticals Issues Voluntary Worldwide Recall of Ruzurgi 10 mg
13 Sep 2021 //
FDA
An incensed Catalyst Pharma sues the FDA
13 Jun 2019 //
ENDPTS
Jacobus prices its rare disease drug at half of what Catalyst charges
12 Jun 2019 //
STAT NEWS
Is Jacobus poised to win physician, payer support for off-label adult LEMS use?
11 Jun 2019 //
ENDPTS
Catalyst dives as FDA approves rival`s rare disease drug
08 May 2019 //
BIOPHARMADIVE
FDA approves Ruzurgi for children with Lambert-Eaton myasthenic syndrome
08 May 2019 //
PHARMA TIMES
Catalyst`s $375K Firdapse could get off-label competition
07 May 2019 //
FIERCE PHARMA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.